



Transfer of Shares of TamaBio to Quon Capital

~ TamaBio: Manufacturer of Artificial Biomembranes for Neurosurgery and Cardiac Surgery ~

M3, Inc. (Headquarters: Tokyo, Japan; CEO: Itaru Tanimura; URL: <https://corporate.m3.com/>; "M3" below) has announced that the Seeds Rocket Limited Liability Partnership (CEO: Kazuhiro Umeda at M3i, Inc.; "Seeds Rocket" below), which develops the seeds rocket business, has transferred its stake (86.4% of outstanding shares) in TamaBio Co.,Ltd (Headquarters: Tokyo, Japan; CEO: Kiyoharu Hoshino; "TamaBio" below), a subsidiary established in April 2016, to an investment fund managed by Quon Capital Co., Ltd. (Headquarters: Tokyo, Japan; CEO: Tetsuya Nagao; "Quon Capital" below).

TamaBio was established in April 2016 as a part of M3's seeds rocket business, using RIKEN's special polymer resin processing technology as its practical fundamental technology. TamaBio has already received manufacture and sales approval (Class IV) for the artificial dura mater DuraBeam® and artificial pericardium Peribeam® from the Ministry of Health, Labour and Welfare. DuraBeam® has been sold nationwide since July 2020, and is currently being used by more than 500 patients and is highly evaluated.

In the future, with the support of Quon Capital, TamaBio will develop its business by gaining approval in promising overseas markets, and also, by taking into consideration developing artificial organs for more critical and promising fields in addition to DuraBeam® and Peribeam®.

■ Quon Capital Overview

Founded: April 2019

Address: ARK Hills Front Tower, 2-23-1 Akasaka, Minato-ku, Tokyo

CEO: Tetsuya Nagao

Business: Investment fund management and administration, management consulting

■ TamaBio Overview

Founded: April 2016

CEO: Kiyoharu Hoshino

Business: Development and sales of medical devices